Optimization of potent and selective quinazolinediones: Inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10314-10328

  Matharu, Daljit S ^a   Flaherty, Daniel P ^a   Simpson, Denise S ^a   Schroeder, Chad E ^a   Chung, Donghoon ^b,c   Yan, Dan ^d   Noah, James W ^c   Jonsson, Colleen B ^b,c   White, E Lucile ^c   Aubé, Jeffrey ^a   Plemper, Richard K ^d   Severson, William E ^b,c   Golden, Jennifer E ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHYLBENZYL) 3 [4 (MORPHOLINE 4 CARBONYL)BENZYL]QUINAZOLINE 2,4(1H,3H) DIONE; 1 (4 METHYLBENZYL) 3 [4 (PIPERIDINE 1 CARBONYL)BENZYL]QUINAZOLINE 2,4(1H,3H) DIONE; 1 (4 METHYLBENZYL) 3 [4 (PYRROLIDINE 1 CARBONYL)BENZYL]QUINAZOLINE 2,4(1H,3H) DIONE; 4 [[1 (2 BROMOBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (3 BROMOBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 BROMOBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 CHLOROBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H)YL] METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 CYANOBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 ETHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 FLUOROBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 ISOPROPYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 METHOXYBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (OXETAN 3 YLMETHYL)BENZAMIDE; 4 [[1 (BENZO[C][1,2,5]OXADIAZOL 5 YLMETHYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[2,4 DIOXO 1 (PYRIDIN 2 YLMETHYL) 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[2,4 DIOXO 1 (PYRIDIN 3 YLMETHYL) 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; 4 [[2,4 DIOXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL] N (3 METHOXYPROPYL)BENZAMIDE; ANTIVIRUS AGENT; N (2 METHOXYETHYL) 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N (3 ETHOXYPROPYL) 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N (3 ISOPROPOXYPROPYL) 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N (3 METHOXYPROPYL) 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N (3 METHOXYPROPYL) 4 [[1 (4 NITROBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N (3 METHOXYPROPYL) 4 [[1 [(5 METHYLISOXAZOL 3 YL)METHYL] 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N (4 METHOXYBUTYL) 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N (CYCLOBUTYLMETHYL) 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; N [3 (DIMETHYLAMINO)PROPYL] 4 [[1 (4 METHYLBENZYL) 2,4 DIOXO 1,2 DIHYDROQUINAZOLIN 3(4H) YL]METHYL]BENZAMIDE; QUINAZOLINE DERIVATIVE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; BENZAMIDE DERIVATIVE; N-(3-METHOXYPROPYL)-4-((1-(4-NITROBENZYL)-2,4-DIOXO-1,2-DIHYDROQUINAZOLIN-3(4H)-YL)METHYL)BENZAMIDE; QUINAZOLINONE DERIVATIVE; RNA DIRECTED RNA POLYMERASE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EC50; ENZYME ACTIVITY; HEP 2 CELL LINE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IC50; NONHUMAN; PROGENY; RECEPTOR BINDING; VIRUS INHIBITION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HEPG2 CELL LINE; METABOLISM; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIROLOGY;

ANTIVIRAL AGENTS; BENZAMIDES; CELL PROLIFERATION; DRUG DESIGN; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUINAZOLINONES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RNA REPLICASE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84920148075     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500902x     Document Type: Article

References (37)

1. Greenough, A. Respiratory syncytial virus infection: clinical features, management, and prophylaxis Curr. Opin. Pulm. Med. 2002, 8, 214-217
2. Wright, P. F.; Cutts, F. T. Generic protocol to examine the incidence of lower respiratory infection due to respiratory syncytial virus inchildren less than 5 years of age; World Health Organization: Geneva, 2000.
3. Wright, M.; Piedimonte, G. Respiratory syncytial virus prevention and therapy: Past, present, and future Pediatr. Pulmonol. 2011, 46, 324-347
4. Falsey, A. R.; Walsh, E. E. Respiratory syncytial virus infection in adults Clin. Microbiol. Rev. 2000, 13, 371-384
5. Enders, G. Medical Microbiology, 4 th ed.; Baron, S., Ed.; University of Texas Medical Branch at Galveston: 1996.
6. Blanco, J. C. G.; Boukhvalova, M. S.; Shirey, K. A.; Prince, G. A.; Vogel, S. N. New insights for development of a safe and protective RSV vaccine Hum. Vaccines 2010, 6, 482-492
7. Graham, B. S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development Immunol. Rev. 2011, 239, 149-166
8. Morris, J. A.; Blount, R. E.; Savage, R. E. Recovery of cytopathic agent from chimpanzees with coryza Proc. Soc. Exp. Biol. Med. 1956, 92, 544-549
9. REBETOL Product Information. Schering Corporation. 1998.
10. Ben Venue Laboratories, I. Virazole, aerosolized ribavirin. In Drug Insert; 2012; http://www.drugs.com/pro/virazole.html.
11. Murata, Y.; Falsey, A. R. Respiratory syncytial virus infection in adults Antivir. Ther. 2007, 12, 659-670
12. Nair, H.; Nokes, D. J.; Gessner, B. D.; Dherani, M.; Madhi, S. A.; Singleton, R. J.; O'Brien, K. L.; Roca, A.; Wright, P. F.; Bruce, N.; Chandran, A.; Theodoratou, E.; Sutanto, A.; Sedyaningsih, E. R.; Ngama, M.; Munywoki, P. K.; Kartasasmita, C.; Simões, E. A. F.; Rudan, I.; Weber, M. W.; Campbell, H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 2010, 375, 1545-1555
13. Sigurs, N. A cohort of children hospitalised with acute RSV bronchiolitis: impact on later respiratory disease Paediatr. Respir. Rev. 2002, 3, 177-183
14. Sigurs, N.; Bjarnason, R.; Sigurbergsson, F.; Kjellman, B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7 Am. J. Respir. Crit. Care Med. 2000, 161, 1501-1507
15. Moore, B. P.; Chung, D. H.; Matharu, D. S.; Golden, J. E.; Maddox, C.; Rasmussen, L.; Noah, J. W.; Sosa, M. I.; Ananthan, S.; Tower, N. A.; White, E. L.; Jia, F.; Prisinzano, T. E.; Aubé, J.; Jonsson, C. B.; Severson, W. E. (S)- N -(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection J. Med. Chem. 2012, 55, 8582-8587
16. Douglas, J. L. In search of a small-molecule inhibitor for respiratory syncytial virus Expert Rev. Anti Infect. Ther. 2004, 2, 625-639
17. Bonavia, A.; Franti, M.; Pusateri Keaney, E.; Kuhen, K.; Seepersaud, M.; Radetich, B.; Shao, J.; Honda, A.; Dewhurst, J.; Balabanis, K.; Monroe, J.; Wolff, K.; Osborne, C.; Lanieri, L.; Hoffmaster, K.; Amin, J.; Markovits, J.; Broome, M.; Skuba, E.; Cornella-Taracido, I.; Joberty, G.; Bouwmeester, T.; Hamann, L.; Tallarico, J. A.; Tommasi, R.; Compton, T.; Bushell, S. M. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV) Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 6739-6744
18. Liuzzi, M.; Mason, S. W.; Cartier, M.; Lawetz, C.; McCollum, R. S.; Dansereau, N.; Bolger, G.; Lapeyre, N.; Gaudette, Y.; Lagace, L.; Massariol, M. J.; Do, F.; Whitehead, P.; Lamarre, L.; Scouten, E.; Bordeleau, J.; Landry, S.; Rancourt, J.; Fazal, G.; Simoneau, B. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase J. Virol. 2005, 79, 13105-13115
19. Chapman, J.; Abbott, E.; Alber, D. G.; Baxter, R. C.; Bithell, S. K.; Henderson, E. A.; Carter, M. C.; Chambers, P.; Chubb, A.; Cockerill, G. S.; Collins, P. L.; Dowdell, V. C. L.; Keegan, S. J.; Kelsey, R. D.; Lockyer, M. J.; Luongo, C.; Najarro, P.; Pickles, R. J.; Simmonds, M.; Taylor, D.; Tyms, S.; Wilson, L. J.; Powell, K. L. RSV604, a novel inhibitor of respiratory syncytial virus replication Antimicrob. Agents Chemother. 2007, 51, 3346-3353
20. Xiong, H.; Foulk, M.; Aschenbrenner, L.; Fan, J.; Tiong-Yip, C.-L.; Johnson, K. D.; Moustakas, D.; Fleming, P. R.; Brown, D. G.; Zhang, M.; Ferguson, D.; Wu, D.; Yu, Q. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor Bioorg. Med. Chem. Lett. 2013, 23, 6789-6793
21. Sudo, K.; Miyazaki, Y.; Kojima, N.; Kobayashi, M.; Suzuki, H.; Shintani, M.; Shimizu, Y. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action Antiviral Res. 2005, 65, 125-131
22. Carter, M. C.; Alber, D. G.; Baxter, R. C.; Bithell, S. K.; Budworth, J.; Chubb, A.; Cockerill, G. S.; Dowdell, V. C.; Henderson, E. A.; Keegan, S. J.; Kelsey, R. D.; Lockyer, M. J.; Stables, J. N.; Wilson, L. J.; Powell, K. L. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus J. Med. Chem. 2006, 49, 2311-2319
23. Sun, Z.; Pan, Y.; Jiang, S.; Lu, L. Respiratory syncytial virus entry inhibitors targeting the F-protein Viruses 2013, 5, 211-225
24. Huntley, C. C.; Weiss, W. J.; Gazumyan, A.; Buklan, A.; Feld, B.; Hu, W.; Jones, T. R.; Murphy, T.; Nikitenko, A. A.; O'Hara, B.; Prince, G.; Quartuccio, S.; Raifeld, Y. E.; Wyde, P.; O'Connell, J. F. RFI-641, a potent respiratory syncytial virus inhibitor Antimicrob. Agents Chemother. 2002, 46, 841-847
25. Douglas, J. L.; Panis, M. L.; Ho, E.; Lin, K. Y.; Krawczyk, S. H.; Grant, D. M.; Cai, R.; Swaminathan, S.; Chen, X.; Cihlar, T. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms Antimicrob. Agents Chemother. 2005, 49, 2460-2466
26. Bonfanti, J. F.; Doublet, F.; Fortin, J.; Lacrampe, J.; Guillemont, J.; Muller, P.; Queguiner, L.; Arnoult, E.; Gevers, T.; Janssens, P.; Szel, H.; Willebrords, R.; Timmerman, P.; Wuyts, K.; Janssens, F.; Sommen, C.; Wigerinck, P.; Andries, K. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship J. Med. Chem. 2007, 50, 4572-4584
27. Cianci, C.; Genovesi, E. V.; Lamb, L.; Medina, I.; Yang, Z.; Zadjura, L.; Yang, H.; D'Arienzo, C.; Sin, N.; Yu, K. L.; Combrink, K.; Li, Z.; Colonno, R.; Meanwell, N.; Clark, J.; Krystal, M. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection Antimicrob. Agents Chemother. 2004, 48, 2448-2454
28. Meanwell, N. A.; Cianci, C. W.; Krystal, M. R. Discovery and development of orally active RSV fusion inhibitors. In Antiviral Drugs; John Wiley & Sons, Inc.: 2011; pp 353-366.
29. Meanwell, N.; Langley, D. Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion: A Focus on Respiratory Syncytial Virus. In Protein-Protein Interactions; Wendt, M. D., Ed.; Springer: Berlin Heidelberg, 2012; Vol. 8, pp 167-196.
30. Taken from: http://clinicaltrials.gov/show/NCT01756482.
31. Chung, D.-H.; Moore, B.; Matharu, D.; Golden, J. E.; Maddox, C.; Rasmussen, L.; Sosa, M.; Ananthan, S.; White, E. L.; Jia, F.; Jonsson, C.; Severson, W. A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus Virol. J. 2013, 10, 1-12
32. Noah, J. W.; Severson, W. E.; Chung, D. H.; Moore, B.; Jia, F.; Xu, X.; Maddox, C.; Rasmussen, L.; Sosa, M. I.; Tower, N. A.; Ananthan, S.; Evans, C. W.; White, E. L.; Jonsson, C.; Matharu, D. S.; Flaherty, D. P.; Simpson, D. S.; Golden, J. E.; Aubé, J. Identification of a series of quinazolinediones as potent, selective, post-entry inhibitors of human respiratory syncytial virus (hRSV) via a cell-based high throughput screen and chemical optimization. In Probe Reports from the NIH Molecular Libraries Program [Internet], National Center for Biotechnology Information (US): 2011; http://www.ncbi.nlm.nih.gov/books/NBK133445/.
33. NIH Molecular Libraries Small Molecule Repository (MLSMR); http://mli.nih.gov/mli/compound-repository/.
34. Noah, J. W.; Severson, W.; Chung, D. H.; Moore, B.; Jia, F.; Xu, X.; Maddox, C.; Rasmussen, L.; Sosa, M. I.; Tower, N. A.; Ananthan, S.; White, E. L.; Jonsson, C.; Matharu, D. S.; Golden, J. E.; Prisinzano, T. E.; Aubé, J. A cell based HTS approach for the discovery of new inhibitors of RSV. In NIH Bookshelf,; National Center for Biotechnology Information: 2011; http://www.ncbi.nlm.nih.gov/books/NBK133442/.
35. Chung, D.-H.; Jonsson, C. B.; Tower, N. A.; Chu, Y.-K.; Sahin, E.; Golden, J. E.; Noah, J. W.; Schroeder, C. E.; Sotsky, J. B.; Sosa, M. I.; Cramer, D. E.; McKellip, S. N.; Rasmussen, L.; White, E. L.; Schmaljohn, C. S.; Julander, J. G.; Smith, J. M.; Filone, C. M.; Connor, J. H.; Sakurai, Y.; Davey, R. A. Discovery of a novel compound with anti-Venezuelan equine encephalitis virus activity that targets the nonstructural protein 2 PLoS Pathog. 2014, 10, e1004213
36. Schroeder, C. E.; Yao, T.; Sotsky, J. B.; Smith, R. A.; Roy, S.; Chu, Y. K.; Guo, H.; Tower, N. A.; Noah, J. W.; McKellip, S.; Sosa, M.; Rasmussen, L.; Smith, L. H.; White, E. L.; Aubé, J.; Jonsson, C. B.; Chung, D.-H.; Golden, J. E. Development of (E)-2-((1,4-dimethylpiperazin-2- ylidene)amino)-5-nitro- N -phenylbenzamide, ML336: novel 2-amidinophenylbenzamides as potent inhibitors of Venezuelan equine encephalitis virus J. Med. Chem. 2014, 57, 8608
37. Yan, D.; Lee, S.; Thakkar, V. D.; Luo, M.; Moore, M. L.; Plemper, R. K. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors Proc. Natl. Acad. Sci. U.S.A. 2014, 111, E3441-E3449